Search
Research
Febrile seizures following measles and varicella vaccines in young children in AustraliaFebrile seizures (FS) are common in childhood with incidence peaking in the second year of life when measles and varicella-containing vaccines are administered.
Research
A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
News & Events
Whooping cough vaccine could be a new weapon in the fight against food allergiesResearchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.
Research
Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and ChildrenHighly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role...
Research
The burden of rotavirus-related illness among young children on the Australian health care systemTo provide estimates of the annual number and cost of hospital admissions, emergency department (ED) visits and general practitioner (GP) visits...
Research
The safety of seasonal influenza vaccines in Australian children in 2013Our objective was to examine influenza vaccine safety in Australian children aged under 10 years in 2013.
Research
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in childrenOur study will be the first to assess vaccine efficacy targeting H. influenzae in children with recurrent PBB, CSLD and bronchiectasis.
Research
Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 monthsA bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...
Research
A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...
Research
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trialIn many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological evidence, we hypothesised that substituting the first aP dose in the routine vaccination schedule with wP vaccine might protect against IgE-mediated food allergy. We aimed to compare reactogenicity, immunogenicity, and IgE-mediated responses of a mixed wP/aP primary schedule versus the standard aP-only schedule.